stocks AstraZeneca Explored Bristol Myers Squibb Acquisition, Reports Indicate Potential $400 Billion Deal
Reports suggest AstraZeneca has explored an acquisition of Bristol Myers Squibb, a potential merger that could create the world's fourth-largest drugmaker by market value with an estimated valuation of $400 billion, though the discussions' status and outcome remain unconfirmed.
15h ago